跳至主要内容
临床试验/NCT01070641
NCT01070641Unknown4 期

RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage

Aga Khan University1 个研究点 分布在 1 个国家目标入组 148 人开始时间: 2002年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
148
试验地点
1
主要终点
Variceal hemorrhage

研究概览

简要总结

Aim To compare Carvedilol with variceal band ligation in the prevention of first variceal bleed.

End points of trial Primary: Variceal hemorrhage Secondary: Death

Study design

Randomised controlled clinical trial. Results analysed for the above end points on an intention-to-treat basis.

详细描述

Patients from the Gastroenterology section of the Aga Khan University, Karachi, with liver cirrhosis and on endoscopy having grade II, or larger oesophageal varices and who have not bled previously from varices.

Method All suitable patients will be recruited after informed consent is given. Randomisation of treatment is by sealed envelopes prepared in batches of 20.

Carvedilol This will be administered as a once daily dose of 12.5mg.

Variceal band ligation Endoscopy will be performed ever two weeks until eradication of oesophageal varices. Eradication is achieved when no varices or only grade I varices (varices which are small and flatten on air insufflations in the oesophagus) are present. Subsequent endoscopy sessions will be progressively less frequent, at intervals of 3 months, 6 months and 12 months thereafter. Should varices recur, the protocol for eradication as described above will be re-instituted.

Follow-up This will take place in a dedicated clinic. First visit is six weeks after initiation of treatment and three monthly thereafter. Clinical and laboratory parameters will be obtained at each visit. All patients with alcoholic liver disease will be asked to provide an up-to-date status on drinking. Treatment will cease upon reaching any of these end-points: variceal haemorrhage, death or liver transplantation. Duration of follow-up is defined as time from randomisation to the above end points or to the last follow-up date available.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with liver cirrhosis and on endoscopy having grade II, or larger oesophageal varices and who have not bled previously from varices.

排除标准

  • Age <18 or > 75 years.
  • Pregnant or lactating patients: patients of childbearing age who are not on contraception.
  • Allergy to Carvedilol.
  • Already on beta blockers or nitrates.
  • Presence of malignancy that will significantly affect survival.
  • Presence of severe systemic illness e.g. cardiorespiratory, active sepsis.
  • Psychiatric disease or learning difficulty that will prevent the granting of informed consent.
  • Presence of obstructive airways disease.

研究组 & 干预措施

Carvedilol

Active Comparator

Each patient will receive Carvedilol 12.5mg QD

干预措施: Carvedilol (Drug)

Esophageal Variceal Band Ligation

Active Comparator

Each patient will undergo for serial esophageal variceal band ligations after 3 weeks of last session till the eradication of varices

干预措施: Esophageal variceal band ligation (Procedure)

结局指标

主要结局

Variceal hemorrhage

时间窗: one year

次要结局

  • death(one year)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验